In vitro activity of various combinations of antimicrobials against carbapenem-resistant Acinetobacter species in Singapore

Journal of Antibiotics

Volumn 62, Issue 12, 2009, Pages 675-679

  Lim, Tze Peng ^a,d   Tan, Thean Yen ^b   Lee, Winnie ^a   Sasikala, Suranthran ^b   Tan, Thuan Tong ^c   Hsu, Li Yang ^d   Kwa, Andrea L ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b CHANGI GENERAL HOSPITAL   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d Dept Medicine Endocrinol Diabet   (Singapore)

Author keywords

Acinetobacter species; Carbapenem resistance; Combination therapy

Indexed keywords

AMIKACIN; CARBAPENEM; CARBAPENEMASE; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; MEROPENEM; METALLO BETA LACTAMASE; MINOCYCLINE; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; RIFAMPICIN; SULTAMICILLIN; TIGECYCLINE;

ACINETOBACTER; ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENTIATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SINGAPORE; STRAIN DIFFERENCE;

ACINETOBACTER; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CARBAPENEMS; COLONY COUNT, MICROBIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; SINGAPORE; TIME FACTORS;

ACINETOBACTER; ACINETOBACTER BAUMANNII;

EID: 73649117137     PISSN: 00218820     EISSN: None     Source Type: Journal    
DOI: 10.1038/ja.2009.99     Document Type: Article

References (32)

1. Gold, H. S. & Moellering, R. C. Jr. Antimicrobial-drug resistance. N. Engl. J. Med. 335, 1445-1453 (1996).
2. Neu, H. C. The crisis in antibiotic resistance. Science 257, 1064-1073 (1992).
3. Landman, D. et al. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned. Arch. Intern. Med. 162, 1515-1520 (2002).
4. Bonomo, R. A. & Szabo, D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin. Infect. Dis. 43(Suppl 2), S49-S56 (2006).
5. Peleg, A. Y., Seifert, H. & Paterson, D. L. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 21, 538-582 (2008).
6. Poirel, L. & Nordmann, P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin. Microbiol. Infect. 12, 826-836 (2006).
7. Maragakis, L. L. & Perl, T. M. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin. Infect. Dis. 46, 1254-1263 (2008).
8. Levin, A. S. et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin. Infect. Dis. 28, 1008-1011 (1999).
9. Centers for Disease Control and Prevention (CDC). Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002-2004. MMWR Morb. Mortal. Wkly. Rep. 53, 1063-1066 (2004).
10. Talbot, G. H. et al. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. 42, 657-668 (2006).
11. Li, J. et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents. Chemother. 50, 2946-2950 (2006).
12. Yau, W. et al. Colistin hetero-resistance in multidrug-resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme. J. Infect. 58, 138-144 (2009).
13. Hsu, L. Y. et al. Antimicrobial drug resistance in Singapore hospitals. Emerg. Infect. Dis. 13, 1944-1947 (2007).
14. Woodford, N. et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int. J. Antimicrob. Agents 27, 351-353 (2006).
15. Brown, S., Young, H. K. & Amyes, S. G. Characterisation of OXA-51, a novel class D carbapenemase found in genetically unrelated clinical strains of Acinetobacter baumannii from Argentina. Clin. Microbiol. Infect. 11, 15-23 (2005).
16. Nordmann, P. & Poirel, L. Emerging carbapenemases in Gram-negative aerobes. Clin. Microbiol. Infect. 8, 321-331 (2002).
17. Turton, J. F. et al. The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii. FEMS Microbiol. Lett. 258, 72-77 (2006).
18. Chen, T. L. et al. Comparison of one-tube multiplex PCR, automated ribotyping and intergenic spacer (ITS) sequencing for rapid identification of Acinetobacter baumannii. Clin. Microbiol. Infect. 13, 801-806 (2007).
19. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Testing: Seventeenth Informational Supplement M100-S17 (CLSI: Wayne, Pennsylvania, USA, 2007).
20. Jaruratanasirikul, S., Sriwiriyajan, S. & Punyo, J. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-h infusion or bolus injection. Antimicrob. Agents. Chemother. 49, 1337-1339 (2005).
21. Gumbo, T. et al. Concentration-dependent mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob. Agents. Chemother. 51, 3781-3788 (2007).
22. Tan, T. T., Widjaya, L., Hsu, L. Y. & Koh, T. H. Characterization of resistance genes among Acinetobacter spp. isolates in Singaporean Hospitals. 18th European Congress of Clinical Microbiology and Infectious Diseases. Barcelona Spain, 2008.
23. Urban, C., Segal-Maurer, S. & Rahal, J. J. Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii. Clin. Infect. Dis. 36, 1268-1274 (2003).
24. Koh, T. H., Sng, L. H., Wang, G. C., Hsu, L. Y. & Zhao, Y. IMP-4 and OXA betalactamases in Acinetobacter baumannii from Singapore. J. Antimicrob. Chemother. 59, 627-632 (2007).
25. Tognim, M. C., Gales, A. C., Penteado, A. P., Silbert, S. & Sader, H. S. Dissemination of IMP-1 metallo-beta-lactamase-producing Acinetobacter species in a Brazilian teaching hospital. Infect. Control. Hosp. Epidemiol. 27, 742-747 (2006).
26. Wang, H. et al. Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. Antimicrob. Agents. Chemother. 51, 4022-4028 (2007).
27. Li, C., Kuti, J. L., Nightingale, C. H. & Nicolau, D. P. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J. Clin. Pharmacol. 46, 1171-1178 (2006).
28. Montero, A. et al. Antibiotic combinations for serious infections caused by carbapenemresistant Acinetobacter baumannii in a mouse pneumonia model. J. Antimicrob. Chemother. 54, 1085-1091 (2004).
29. Saballs, M. et al. Rifampicin/imipenem combination in the treatment of carbapenemresistant Acinetobacter baumannii infections. J. Antimicrob. Chemother. 58, 697-700 (2006).
30. Wieczorek, P. et al. Multidrug resistant Acinetobacter baumannii-the role of AdeABC (RND family) efflux pump in resistance to antibiotics. Folia. Histochem. Cytobiol. 46, 257-267 (2008).
31. Koh, T. H., Sng, L. H., Wang, G. C., Hsu, L. Y. & Zhao, Y. Carbapenemase and efflux pump genes in Acinetobacter calcoaceticus-Acinetobacter baumannii complex strains from Singapore. J. Antimicrob. Chemother. 60, 1173-1174 (2007).
32. Song, J. Y. et al. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenemresistant Acinetobacter baumannii. J. Antimicrob. Chemother. 60, 317-322 (2007).